175.5K XNYS Volume
XNYS 25 Mar, 2025 1:22 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 26.95 per share. | 18 Mar 2025 | 39 | 8,812 (0%) | 0% | 26.9 | 1,051 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 27.85 per share. | 18 Mar 2025 | 81 | 8,731 (0%) | 0% | 27.9 | 2,256 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 28.29 per share. | 18 Mar 2025 | 7 | 8,724 (0%) | 0% | 28.3 | 198 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 25.32 per share. | 17 Mar 2025 | 3,496 | 139,134 (0%) | 0% | 25.3 | 88,519 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.04 per share. | 18 Feb 2025 | 5,771 | 105,514 (0%) | 0% | 30.0 | 173,377 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 18 Feb 2025 | 96 | 105,418 (0%) | 0% | 30 | 2,880 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 30.06 per share. | 18 Feb 2025 | 3,519 | 741,197 (2%) | 0% | 30.1 | 105,764 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 18 Feb 2025 | 177 | 741,020 (2%) | 0% | 30 | 5,310 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 29.72 per share. | 18 Feb 2025 | 3,496 | 142,630 (0%) | 0% | 29.7 | 103,901 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 13 Feb 2025 | 28,759 | 116,174 (0%) | 0% | 30 | 862,770 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.09 per share. | 13 Feb 2025 | 4,889 | 111,285 (0%) | 0% | 30.1 | 147,088 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 29.70 per share. | 13 Feb 2025 | 11,616 | 218,135 (0%) | 0% | 29.7 | 345,001 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 13 Feb 2025 | 16,005 | 748,302 (2%) | 0% | 30.0 | 480,152 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 30.13 per share. | 13 Feb 2025 | 3,586 | 744,716 (2%) | 0% | 30.1 | 108,039 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 29.52 per share. | 07 Feb 2025 | 300 | 229,751 (0%) | 0% | 29.5 | 8,857 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 29.50 per share. | 05 Feb 2025 | 720 | 230,051 (0%) | 0% | 29.5 | 21,241 | Common Stock |
| Gillian Munson | Director | Grant, award, or other acquisition of securities at price $ 28.46 per share. | 31 Jan 2025 | 351 | 37,074 (0%) | 0% | 28.5 | 9,989 | Common Stock |
| Lainie Goldstein | Director | Grant, award, or other acquisition of securities at price $ 28.46 per share. | 31 Jan 2025 | 351 | 41,455 (0%) | 0% | 28.5 | 9,989 | Common Stock |
| Edward L. Cahill | Director | Grant, award, or other acquisition of securities at price $ 28.46 per share. | 31 Jan 2025 | 351 | 47,383 (0%) | 0% | 28.5 | 9,989 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | 31 Jan 2025 | 13,653 | 0 | - | - | Stock Option (Right to Buy) | ||
| Amy Beth VanDuyn | SVP, Human Resources | 31 Jan 2025 | 13,653 | 128,387 (0%) | 0% | 0.8 | 11,195 | Common Stock | |
| Evan Roberts | Chief Operating Officer | 31 Jan 2025 | 30,000 | 794,307 (2%) | 0% | 0.8 | 25,200 | Common Stock | |
| Evan Roberts | Chief Operating Officer | 31 Jan 2025 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 29.68 per share. | 29 Jan 2025 | 500 | 230,771 (0%) | 0% | 29.7 | 14,841 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 28.50 per share. | 27 Jan 2025 | 6,235 | 146,126 (0%) | 0% | 28.5 | 177,698 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 28.15 per share. | 27 Jan 2025 | 1,979 | 152,361 (0%) | 0% | 28.2 | 55,710 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.15 per share. | 27 Jan 2025 | 7,923 | 1,260,200 (3%) | 0% | 28.2 | 223,036 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 27.18 per share. | 27 Jan 2025 | 18,325 | 1,268,123 (3%) | 0% | 27.2 | 498,161 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 27.18 per share. | 27 Jan 2025 | 7,481 | 767,542 (2%) | 0% | 27.2 | 203,369 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 28.15 per share. | 27 Jan 2025 | 3,235 | 764,307 (2%) | 0% | 28.2 | 91,067 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 27.18 per share. | 27 Jan 2025 | 8,158 | 234,798 (0%) | 0% | 27.2 | 221,774 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 28.15 per share. | 27 Jan 2025 | 3,527 | 231,271 (0%) | 0% | 28.2 | 99,287 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 27.18 per share. | 27 Jan 2025 | 2,426 | 115,783 (0%) | 0% | 27.2 | 65,950 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 28.15 per share. | 27 Jan 2025 | 1,049 | 114,734 (0%) | 0% | 28.2 | 29,530 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.18 per share. | 27 Jan 2025 | 3,360 | 146,386 (0%) | 0% | 27.2 | 91,341 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.15 per share. | 27 Jan 2025 | 1,453 | 144,933 (0%) | 0% | 28.2 | 40,903 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 27.18 per share. | 27 Jan 2025 | 4,577 | 154,340 (0%) | 0% | 27.2 | 124,425 | Common Stock |
| Yvonne Hui | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 28.00 per share. | 24 Jan 2025 | 127 | 25,647 (0%) | 0% | 28 | 3,556 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 12,791 | 158,917 (0%) | 0% | 0 | Common Stock | |
| Chaim Indig | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 48,910 | 1,286,448 (3%) | 0% | 0 | Common Stock | |
| Evan Roberts | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 19,564 | 775,023 (2%) | 0% | 0 | Common Stock | |
| David Linetsky | SVP, Life Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 19,564 | 242,956 (0%) | 0% | 0 | Common Stock | |
| Amy Beth VanDuyn | SVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 7,900 | 118,209 (0%) | 0% | 0 | Common Stock | |
| Balaji Gandhi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 7,900 | 149,746 (0%) | 0% | 0 | Common Stock | |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 21 Jan 2025 | 8,426 | 146,126 (0%) | 0% | 27.3 | 230,120 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 21 Jan 2025 | 21,692 | 1,237,538 (3%) | 0% | 27.3 | 592,424 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 21 Jan 2025 | 12,749 | 755,459 (2%) | 0% | 27.3 | 348,184 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 21 Jan 2025 | 13,873 | 223,392 (0%) | 0% | 27.3 | 378,881 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 21 Jan 2025 | 4,720 | 110,309 (0%) | 0% | 27.3 | 128,907 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.31 per share. | 21 Jan 2025 | 5,827 | 141,846 (0%) | 0% | 27.3 | 159,139 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 26.98 per share. | 15 Jan 2025 | 1,089 | 154,552 (0%) | 0% | 27.0 | 29,383 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 26.87 per share. | 15 Jan 2025 | 3,496 | 155,641 (0%) | 0% | 26.9 | 93,938 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.98 per share. | 15 Jan 2025 | 2,990 | 1,259,230 (3%) | 0% | 27.0 | 80,674 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 26.98 per share. | 15 Jan 2025 | 1,785 | 768,208 (2%) | 0% | 27.0 | 48,162 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 26.98 per share. | 15 Jan 2025 | 1,946 | 237,265 (0%) | 0% | 27.0 | 52,506 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 26.98 per share. | 15 Jan 2025 | 604 | 115,029 (0%) | 0% | 27.0 | 16,297 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.98 per share. | 15 Jan 2025 | 836 | 147,673 (0%) | 0% | 27.0 | 22,556 | Common Stock |
| Yvonne Hui | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 26.87 per share. | 15 Jan 2025 | 381 | 25,774 (0%) | 0% | 26.9 | 10,237 | Common Stock |
| Yvonne Hui | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 26.38 per share. | 14 Jan 2025 | 362 | 26,155 (0%) | 0% | 26.4 | 9,548 | Common Stock |
| Yvonne Hui | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 27.85 per share. | 10 Jan 2025 | 388 | 26,517 (0%) | 0% | 27.9 | 10,806 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 26.61 per share. | 06 Jan 2025 | 3,982 | 159,137 (0%) | 0% | 26.6 | 105,943 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.61 per share. | 06 Jan 2025 | 5,375 | 1,262,220 (3%) | 0% | 26.6 | 143,005 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 27.00 per share. | 06 Jan 2025 | 7,319 | 772,674 (2%) | 0% | 27 | 197,613 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 26.61 per share. | 06 Jan 2025 | 2,873 | 779,993 (2%) | 0% | 26.6 | 76,438 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 26.61 per share. | 06 Jan 2025 | 3,133 | 239,211 (0%) | 0% | 26.6 | 83,355 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 26.61 per share. | 06 Jan 2025 | 1,311 | 115,633 (0%) | 0% | 26.6 | 34,880 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.61 per share. | 06 Jan 2025 | 3,195 | 148,509 (0%) | 0% | 26.6 | 85,005 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 46,525 | 163,119 (0%) | 0% | 0 | Common Stock | |
| Chaim Indig | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 46,948 | 1,267,595 (3%) | 0% | 0 | Common Stock | |
| Evan Roberts | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 53,990 | 782,866 (2%) | 0% | 0 | Common Stock | |
| David Linetsky | SVP, Life Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 53,990 | 242,344 (0%) | 0% | 0 | Common Stock | |
| Amy Beth VanDuyn | SVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 23,474 | 116,944 (0%) | 0% | 0 | Common Stock | |
| Balaji Gandhi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 53,990 | 151,704 (0%) | 0% | 0 | Common Stock | |
| Allison Hoffman | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 17.57 per share. | 31 Dec 2024 | 298 | 116,594 (0%) | 0% | 17.6 | 5,236 | Common Stock |
| Yvonne Hui | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 17.57 per share. | 31 Dec 2024 | 388 | 27,193 (0%) | 0% | 17.6 | 6,817 | Common Stock |
| Linetsky David | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 25.38 per share. | 18 Dec 2024 | 24 | 8,851 (0%) | 0% | 25.4 | 609 | Common Stock |
| Hoffman Allison | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 24.88 per share. | 18 Dec 2024 | 3,495 | 116,296 (0%) | 0% | 24.9 | 86,956 | Common Stock |
| Linetsky David | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 26.00 per share. | 16 Dec 2024 | 2 | 8,875 (0%) | 0% | 26 | 52 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 25.03 per share. | 16 Dec 2024 | 59 | 8,877 (0%) | 0% | 25.0 | 1,477 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 24.89 per share. | 16 Dec 2024 | 35 | 8,936 (0%) | 0% | 24.9 | 871 | Common Stock |
| Michael Weintraub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.71 per share. | 13 Dec 2024 | 20,565 | 263,392 (0%) | 0% | 4.7 | 96,861 | Common Stock |
| Michael Weintraub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2024 | 861 | 16,887 | - | - | Stock Option (Right to Buy) | |
| Michael Weintraub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2024 | 20,565 | 17,748 | - | - | Stock Option (Right to Buy) | |
| Michael Weintraub | Director | Sale of securities on an exchange or to another person at price $ 25.26 per share. | 13 Dec 2024 | 861 | 242,827 (0%) | 0% | 25.3 | 21,752 | Common Stock |
| Michael Weintraub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.71 per share. | 13 Dec 2024 | 861 | 243,688 (0%) | 0% | 4.7 | 4,055 | Common Stock |
| Michael Weintraub | Director | Sale of securities on an exchange or to another person at price $ 25.04 per share. | 13 Dec 2024 | 20,565 | 242,827 (0%) | 0% | 25.0 | 515,038 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 24.85 per share. | 11 Dec 2024 | 11,853 | 188,354 (0%) | 0% | 24.9 | 294,559 | Common Stock |
| Michael Weintraub | Director | Sale of securities on an exchange or to another person at price $ 25.10 per share. | 11 Dec 2024 | 18,574 | 242,827 (0%) | 0% | 25.1 | 466,191 | Common Stock |
| Michael Weintraub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.71 per share. | 11 Dec 2024 | 18,574 | 261,401 (0%) | 0% | 4.7 | 87,484 | Common Stock |
| Michael Weintraub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2024 | 18,574 | 38,313 | - | - | Stock Option (Right to Buy) | |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 24.09 per share. | 10 Dec 2024 | 25,000 | 728,876 (2%) | 0% | 24.1 | 602,160 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 20.93 per share. | 03 Dec 2024 | 25,447 | 93,470 (0%) | 0% | 20.9 | 532,560 | Common Stock |
| Michael Weintraub | Director | Sale of securities on an exchange or to another person at price $ 21.01 per share. | 02 Dec 2024 | 15,152 | 242,827 (0%) | 0% | 21.0 | 318,368 | Common Stock |
| Michael Weintraub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 15,152 | 11 | - | - | Stock Options (Right to Buy) | |
| Michael Weintraub | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.03 per share. | 02 Dec 2024 | 15,152 | 257,979 (0%) | 0% | 2.0 | 30,759 | Common Stock |
| Edward L. Cahill | Director | Grant, award, or other acquisition of securities at price $ 18.29 per share. | 31 Oct 2024 | 546 | 47,032 (0%) | 0% | 18.3 | 9,986 | Common Stock |
| Lainie Goldstein | Director | Grant, award, or other acquisition of securities at price $ 18.29 per share. | 31 Oct 2024 | 546 | 41,104 (0%) | 0% | 18.3 | 9,986 | Common Stock |
| Gillian Munson | Director | Grant, award, or other acquisition of securities at price $ 18.29 per share. | 31 Oct 2024 | 546 | 36,723 (0%) | 0% | 18.3 | 9,986 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 20.49 per share. | 18 Oct 2024 | 1,100 | 200,207 (0%) | 0% | 20.5 | 22,539 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 21.02 per share. | 15 Oct 2024 | 1,212 | 119,791 (0%) | 0% | 21.0 | 25,482 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 21.03 per share. | 15 Oct 2024 | 3,089 | 1,220,647 (3%) | 0% | 21.0 | 64,947 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 21.02 per share. | 15 Oct 2024 | 1,843 | 753,876 (2%) | 0% | 21.0 | 38,749 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 21.02 per share. | 15 Oct 2024 | 2,011 | 201,307 (0%) | 0% | 21.0 | 42,281 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 21.03 per share. | 15 Oct 2024 | 624 | 118,917 (0%) | 0% | 21.0 | 13,120 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.03 per share. | 15 Oct 2024 | 864 | 97,714 (0%) | 0% | 21.0 | 18,166 | Common Stock |
| Yvonne Hui | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 20.91 per share. | 15 Oct 2024 | 2,485 | 27,534 (0%) | 0% | 20.9 | 51,961 | Common Stock |
| Yvonne Hui | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 21.33 per share. | 15 Oct 2024 | 423 | 26,805 (0%) | 0% | 21.3 | 9,023 | Common Stock |
| Yvonne Hui | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 21.03 per share. | 15 Oct 2024 | 306 | 27,228 (0%) | 0% | 21.0 | 6,434 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 24.04 per share. | 19 Sep 2024 | 24 | 8,971 (0%) | 0% | 24.0 | 577 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 24.08 per share. | 17 Sep 2024 | 61 | 8,995 (0%) | 0% | 24.1 | 1,469 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 24.78 per share. | 17 Sep 2024 | 36 | 9,056 (0%) | 0% | 24.8 | 892 | Common Stock |
| Lisa C. Egbuonu-Davis | Director | Sale of securities on an exchange or to another person at price $ 23.03 per share. | 12 Sep 2024 | 1,400 | 18,139 (0%) | 0% | 23.0 | 32,239 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 23.36 per share. | 10 Sep 2024 | 2,072 | 121,003 (0%) | 0% | 23.4 | 48,402 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 23.25 per share. | 10 Sep 2024 | 2,622 | 123,075 (0%) | 0% | 23.3 | 60,962 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 23.25 per share. | 10 Sep 2024 | 5,295 | 1,223,736 (3%) | 0% | 23.3 | 123,110 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 23.25 per share. | 10 Sep 2024 | 3,148 | 755,719 (2%) | 0% | 23.3 | 73,192 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 23.25 per share. | 10 Sep 2024 | 1,716 | 203,318 (0%) | 0% | 23.3 | 39,897 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 23.25 per share. | 10 Sep 2024 | 95 | 9,092 (0%) | 0% | 23.3 | 2,209 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 23.25 per share. | 10 Sep 2024 | 737 | 119,541 (0%) | 0% | 23.2 | 17,135 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 23.25 per share. | 10 Sep 2024 | 3,502 | 98,578 (0%) | 0% | 23.3 | 81,422 | Common Stock |
| Yvonne Hui | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 23.25 per share. | 10 Sep 2024 | 744 | 30,019 (0%) | 0% | 23.3 | 17,298 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2024 | 4,694 | 125,697 (0%) | 0% | - | Common Stock | |
| Chaim Indig | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2024 | 9,670 | 1,229,031 (3%) | 0% | - | Common Stock | |
| Evan Roberts | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2024 | 5,633 | 758,867 (2%) | 0% | - | Common Stock | |
| David Linetsky | SVP, Life Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2024 | 2,816 | 205,034 (0%) | 0% | - | Common Stock | |
| David Linetsky | SVP, Life Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2024 | 234 | 9,187 (0%) | 0% | - | Common Stock | |
| Amy Beth VanDuyn | SVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2024 | 1,642 | 120,278 (0%) | 0% | - | Common Stock | |
| Balaji Gandhi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2024 | 5,633 | 102,080 (0%) | 0% | - | Common Stock | |
| Yvonne Hui | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2024 | 2,049 | 30,763 (0%) | 0% | - | Common Stock | |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 26.03 per share. | 26 Aug 2024 | 14,110 | 121,003 (0%) | 0% | 26.0 | 367,241 | Common Stock |
| David Linetsky | SVP, Life Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 2,000 | 8,953 (0%) | 0% | 0 | Common Stock | |
| Edward L. Cahill | Director | Grant, award, or other acquisition of securities at price $ 24.95 per share. | 31 Jul 2024 | 400 | 46,486 (0%) | 0% | 25.0 | 9,980 | Common Stock |
| Lainie Goldstein | Director | Grant, award, or other acquisition of securities at price $ 24.95 per share. | 31 Jul 2024 | 400 | 40,558 (0%) | 0% | 25.0 | 9,980 | Common Stock |
| Gillian Munson | Director | Grant, award, or other acquisition of securities at price $ 24.95 per share. | 31 Jul 2024 | 400 | 36,177 (0%) | 0% | 25.0 | 9,980 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 29 Jul 2024 | 7 | 1,219,368 (3%) | 0% | 2 | 14 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jul 2024 | 7 | 0 | - | - | Stock Option (Right to Buy) | |
| Chaim Indig | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 24.71 per share. | 29 Jul 2024 | 7 | 1,219,361 (3%) | 0% | 24.7 | 173 | Common Stock |
| Mark Douglas Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.71 per share. | 18 Jul 2024 | 7,000 | 37,653 (0%) | 0% | 4.7 | 32,970 | Common Stock |
| Mark Douglas Smith | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 18 Jul 2024 | 7,000 | 30,653 (0%) | 0% | 25 | 175,000 | Common Stock |
| Mark Douglas Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jul 2024 | 7,000 | 58,193 | - | - | Stock Option | |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 23.74 per share. | 16 Jul 2024 | 800 | 135,113 (0%) | 0% | 23.7 | 18,988 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 23.74 per share. | 16 Jul 2024 | 2,644 | 1,219,361 (3%) | 0% | 23.7 | 62,757 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 23.74 per share. | 16 Jul 2024 | 1,669 | 753,234 (2%) | 0% | 23.7 | 39,615 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 23.74 per share. | 16 Jul 2024 | 1,820 | 202,218 (0%) | 0% | 23.7 | 43,199 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 23.74 per share. | 16 Jul 2024 | 374 | 118,636 (0%) | 0% | 23.7 | 8,877 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 23.74 per share. | 16 Jul 2024 | 783 | 96,447 (0%) | 0% | 23.7 | 18,585 | Common Stock |
| Yvonne Hui | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 22.82 per share. | 15 Jul 2024 | 13,000 | 28,997 (0%) | 0% | 22.8 | 296,660 | Common Stock |
| Yvonne Hui | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 23.73 per share. | 15 Jul 2024 | 283 | 28,714 (0%) | 0% | 23.7 | 6,717 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 18.02 per share. | 28 Jun 2024 | 292 | 135,913 (0%) | 0% | 18.0 | 5,262 | Common Stock |
| Yvonne Hui | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 18.02 per share. | 28 Jun 2024 | 740 | 15,997 (0%) | 0% | 18.0 | 13,335 | Common Stock |
| Edward L. Cahill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 8,490 | 54,576 (0%) | 0% | 0 | Common Stock | |
| Lainie Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 8,490 | 40,158 (0%) | 0% | 0 | Common Stock | |
| Gillian Munson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 8,490 | 35,777 (0%) | 0% | 0 | Common Stock | |
| Mark Douglas Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 8,490 | 30,653 (0%) | 0% | 0 | Common Stock | |
| Michael Weintraub | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 8,490 | 189,027 (0%) | 0% | 0 | Common Stock | |
| Ramin Sayar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 8,490 | 26,735 (0%) | 0% | 0 | Common Stock | |
| Lisa C. Egbuonu-Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 8,490 | 19,539 (0%) | 0% | 0 | Common Stock | |
| Janet M. Gunzburg | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 20.24 per share. | 21 Jun 2024 | 114 | 34,820 (0%) | 0% | 20.2 | 2,307 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 20.22 per share. | 21 Jun 2024 | 27 | 6,953 (0%) | 0% | 20.2 | 546 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 19.73 per share. | 18 Jun 2024 | 66 | 6,980 (0%) | 0% | 19.7 | 1,302 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 19.20 per share. | 18 Jun 2024 | 41 | 7,046 (0%) | 0% | 19.2 | 787 | Common Stock |
| Janet M. Gunzburg | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 01 May 2024 | 286 | 34,934 (0%) | 0% | 21 | 6,006 | Common Stock |
| Edward L. Cahill | Director | Grant, award, or other acquisition of securities at price $ 20.74 per share. | 30 Apr 2024 | 482 | 46,086 (0%) | 0% | 20.7 | 9,997 | Common Stock |
| Lainie Goldstein | Director | Grant, award, or other acquisition of securities at price $ 20.74 per share. | 30 Apr 2024 | 482 | 31,668 (0%) | 0% | 20.7 | 9,997 | Common Stock |
| Gillian Munson | Director | Grant, award, or other acquisition of securities at price $ 20.74 per share. | 30 Apr 2024 | 482 | 27,287 (0%) | 0% | 20.7 | 9,997 | Common Stock |
| Janet M. Gunzburg | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 22.85 per share. | 18 Apr 2024 | 912 | 35,220 (0%) | 0% | 22.8 | 20,836 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 22.85 per share. | 18 Apr 2024 | 269 | 7,087 (0%) | 0% | 22.8 | 6,146 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 22.86 per share. | 15 Apr 2024 | 3,392 | 1,222,005 (3%) | 0% | 22.9 | 77,532 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 22.86 per share. | 15 Apr 2024 | 2,029 | 754,903 (2%) | 0% | 22.9 | 46,378 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 22.86 per share. | 15 Apr 2024 | 2,212 | 204,038 (0%) | 0% | 22.9 | 50,561 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 22.86 per share. | 15 Apr 2024 | 685 | 119,010 (0%) | 0% | 22.9 | 15,657 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 22.86 per share. | 15 Apr 2024 | 1,238 | 135,621 (0%) | 0% | 22.9 | 28,297 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.86 per share. | 15 Apr 2024 | 948 | 97,230 (0%) | 0% | 22.9 | 21,669 | Common Stock |
| Janet M. Gunzburg | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 23.10 per share. | 10 Apr 2024 | 2,768 | 36,132 (0%) | 0% | 23.1 | 63,928 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 23.42 per share. | 08 Apr 2024 | 4,626 | 136,859 (0%) | 0% | 23.4 | 108,360 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 23.02 per share. | 08 Apr 2024 | 55 | 141,485 (0%) | 0% | 23.0 | 1,266 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 22.62 per share. | 08 Apr 2024 | 5,494 | 141,540 (0%) | 0% | 22.6 | 124,253 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 22.62 per share. | 08 Apr 2024 | 11,923 | 1,225,517 (3%) | 0% | 22.6 | 269,652 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 23.02 per share. | 08 Apr 2024 | 120 | 1,225,397 (3%) | 0% | 23.0 | 2,762 | Common Stock |
| Evan Roberts | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.03 per share. | 08 Apr 2024 | 23,330 | 756,932 (2%) | 0% | 2.0 | 47,360 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 22.62 per share. | 08 Apr 2024 | 7,106 | 733,674 (2%) | 0% | 22.6 | 160,710 | Common Stock |
| Evan Roberts | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2024 | 23,330 | 0 | - | - | Stock Option | |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 23.01 per share. | 08 Apr 2024 | 72 | 733,602 (2%) | 0% | 23.0 | 1,657 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 23.03 per share. | 08 Apr 2024 | 39 | 206,250 (0%) | 0% | 23.0 | 898 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 22.62 per share. | 08 Apr 2024 | 3,875 | 206,289 (0%) | 0% | 22.6 | 87,637 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 22.62 per share. | 08 Apr 2024 | 245 | 7,358 (0%) | 0% | 22.6 | 5,541 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 23.00 per share. | 08 Apr 2024 | 2 | 7,356 (0%) | 0% | 23 | 46 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 23.03 per share. | 08 Apr 2024 | 34 | 123,463 (0%) | 0% | 23.0 | 783 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 22.62 per share. | 08 Apr 2024 | 3,320 | 123,497 (0%) | 0% | 22.6 | 75,085 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 23.43 per share. | 08 Apr 2024 | 3,768 | 119,695 (0%) | 0% | 23.4 | 88,277 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.62 per share. | 08 Apr 2024 | 7,700 | 98,256 (0%) | 0% | 22.6 | 174,144 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 23.01 per share. | 08 Apr 2024 | 78 | 98,178 (0%) | 0% | 23.0 | 1,795 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 10,175 | 147,034 (0%) | 0% | - | Common Stock | |
| Janet M. Gunzburg | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 4,477 | 43,426 (0%) | 0% | - | Common Stock | |
| Chaim Indig | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 20,961 | 1,237,440 (3%) | 0% | - | Common Stock | |
| Evan Roberts | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 12,210 | 740,780 (2%) | 0% | - | Common Stock | |
| David Linetsky | SVP, Life Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 6,105 | 210,164 (0%) | 0% | - | Common Stock | |
| David Linetsky | SVP, Life Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 508 | 7,603 (0%) | 0% | - | Common Stock | |
| Amy Beth VanDuyn | SVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 7,122 | 126,817 (0%) | 0% | - | Common Stock | |
| Balaji Gandhi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 11,926 | 105,956 (0%) | 0% | - | Common Stock | |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 23.21 per share. | 25 Mar 2024 | 3,504 | 94,030 (0%) | 0% | 23.2 | 81,332 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 23.48 per share. | 21 Mar 2024 | 24,962 | 729,570 (2%) | 0% | 23.5 | 586,228 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 24.46 per share. | 21 Mar 2024 | 1,000 | 728,570 (2%) | 0% | 24.5 | 24,457 | Common Stock |
| Janet M. Gunzburg | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 23.66 per share. | 20 Mar 2024 | 137 | 38,949 (0%) | 0% | 23.7 | 3,241 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 23.67 per share. | 20 Mar 2024 | 30 | 7,095 (0%) | 0% | 23.7 | 710 | Common Stock |
| Janet M. Gunzburg | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 23.27 per share. | 19 Mar 2024 | 2,817 | 40,609 (0%) | 0% | 23.3 | 65,561 | Common Stock |
| Janet M. Gunzburg | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 23.00 per share. | 19 Mar 2024 | 17 | 38,900 (0%) | 0% | 23 | 391 | Common Stock |
| Janet M. Gunzburg | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 22.62 per share. | 19 Mar 2024 | 1,692 | 38,917 (0%) | 0% | 22.6 | 38,266 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 22.22 per share. | 18 Mar 2024 | 46 | 7,527 (0%) | 0% | 22.2 | 1,022 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 23.27 per share. | 18 Mar 2024 | 402 | 7,125 (0%) | 0% | 23.3 | 9,356 | Common Stock |
| M. Janet Gunzburg | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 28.00 per share. | 09 Feb 2024 | 480 | 39,086 (0%) | 0% | 28 | 13,440 | Common Stock |
| Gunzburg M. Janet | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 27.00 per share. | 02 Feb 2024 | 480 | 39,566 (0%) | 0% | 27 | 12,960 | Common Stock |
| Munson Gillian | Director | Grant, award, or other acquisition of securities at price $ 25.48 per share. | 31 Jan 2024 | 392 | 26,805 (0%) | 0% | 25.5 | 9,988 | Common Stock |
| Lainie Goldstein | Director | Grant, award, or other acquisition of securities at price $ 25.48 per share. | 31 Jan 2024 | 392 | 31,186 (0%) | 0% | 25.5 | 9,988 | Common Stock |
| Cahill Edward L. | Director | Grant, award, or other acquisition of securities at price $ 25.48 per share. | 31 Jan 2024 | 392 | 45,604 (0%) | 0% | 25.5 | 9,988 | Common Stock |
| Michael Weintraub | Director | 31 Jan 2024 | 144,845 | 28,989 (0%) | 0% | 0 | Common Stock | ||
| Michael Weintraub | Director | 31 Jan 2024 | 6,703 | 28,989 (0%) | 0% | 0 | Common Stock | ||
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 24.55 per share. | 16 Jan 2024 | 932 | 106,726 (0%) | 0% | 24.5 | 22,876 | Common Stock |
| Michael Davidoff J. | SVP, Payer Business | Sale of securities on an exchange or to another person at price $ 24.55 per share. | 16 Jan 2024 | 1,310 | 91,068 (0%) | 0% | 24.5 | 32,155 | Common Stock |
| Hoffman Allison | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 24.55 per share. | 16 Jan 2024 | 1,316 | 144,464 (0%) | 0% | 24.5 | 32,302 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 24.55 per share. | 16 Jan 2024 | 2,247 | 795,613 (2%) | 0% | 24.5 | 55,154 | Common Stock |
| Gandhi Balaji | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 24.12 per share. | 16 Jan 2024 | 9,192 | 97,534 (0%) | 0% | 24.1 | 221,726 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Sale of securities on an exchange or to another person at price $ 24.12 per share. | 16 Jan 2024 | 17,677 | 73,391 (0%) | 0% | 24.1 | 426,398 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 24.12 per share. | 16 Jan 2024 | 63,931 | 1,216,479 (3%) | 0% | 24.1 | 1,542,118 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 24.55 per share. | 16 Jan 2024 | 2,318 | 234,718 (0%) | 0% | 24.5 | 56,896 | Common Stock |
| Indig Chaim | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 24.55 per share. | 16 Jan 2024 | 3,586 | 1,280,410 (3%) | 0% | 24.5 | 88,020 | Common Stock |
| Hoffman Allison | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 24.12 per share. | 16 Jan 2024 | 7,605 | 136,859 (0%) | 0% | 24.1 | 183,445 | Common Stock |
| Roberts Evan | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 24.12 per share. | 16 Jan 2024 | 41,081 | 754,532 (2%) | 0% | 24.1 | 990,939 | Common Stock |
| Linetsky David | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 24.12 per share. | 16 Jan 2024 | 30,659 | 204,059 (0%) | 0% | 24.1 | 739,544 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 24.55 per share. | 16 Jan 2024 | 738 | 129,908 (0%) | 0% | 24.5 | 18,115 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 24.12 per share. | 16 Jan 2024 | 10,213 | 119,695 (0%) | 0% | 24.1 | 246,354 | Common Stock |
| Janet M. Gunzburg | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 24.11 per share. | 12 Jan 2024 | 205 | 40,374 (0%) | 0% | 24.1 | 4,943 | Common Stock |
| Gunzburg Janet M. | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 25.99 per share. | 12 Jan 2024 | 328 | 40,046 (0%) | 0% | 26.0 | 8,525 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 30,500 | 145,780 (0%) | 0% | 0 | Common Stock | |
| Chaim Indig | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 42,000 | 1,283,996 (3%) | 0% | 0 | Common Stock | |
| Gandhi Balaji | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 22,000 | 107,658 (0%) | 0% | 0 | Common Stock | |
| David Linetsky | SVP, Life Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 22,000 | 237,036 (0%) | 0% | 0 | Common Stock | |
| VanDuyn Beth Amy | SVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 12,500 | 130,646 (0%) | 0% | 0 | Common Stock | |
| Roberts Evan | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 22,000 | 797,860 (2%) | 0% | 0 | Common Stock | |
| Hoffman Allison | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 19.68 per share. | 31 Dec 2023 | 255 | 115,280 (0%) | 0% | 19.7 | 5,018 | Common Stock |
| Gunzburg M. Janet | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 23.72 per share. | 19 Dec 2023 | 118 | 40,579 (0%) | 0% | 23.7 | 2,799 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 23.15 per share. | 18 Dec 2023 | 234 | 7,598 (0%) | 0% | 23.2 | 5,418 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 23.72 per share. | 18 Dec 2023 | 25 | 7,573 (0%) | 0% | 23.7 | 593 | Common Stock |
| Janet M. Gunzburg | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 13.38 per share. | 01 Nov 2023 | 298 | 40,697 (0%) | 0% | 13.4 | 3,988 | Common Stock |
| Edward L. Cahill | Director | Grant, award, or other acquisition of securities at price $ 13.66 per share. | 31 Oct 2023 | 732 | 45,212 (0%) | 0% | 13.7 | 9,999 | Common Stock |
| Lainie Goldstein | Director | Grant, award, or other acquisition of securities at price $ 13.66 per share. | 31 Oct 2023 | 732 | 30,794 (0%) | 0% | 13.7 | 9,999 | Common Stock |
| Gillian Munson | Director | Grant, award, or other acquisition of securities at price $ 13.66 per share. | 31 Oct 2023 | 732 | 26,413 (0%) | 0% | 13.7 | 9,999 | Common Stock |
| Evan Roberts | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2023 | 30,000 | 23,330 | - | - | Stock Option | |
| Evan Roberts | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.03 per share. | 31 Oct 2023 | 30,000 | 775,860 (2%) | 0% | 2.0 | 60,900 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 16.61 per share. | 16 Oct 2023 | 1,297 | 115,025 (0%) | 0% | 16.6 | 21,542 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.61 per share. | 16 Oct 2023 | 3,295 | 1,241,996 (3%) | 0% | 16.6 | 54,727 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 16.61 per share. | 16 Oct 2023 | 1,971 | 745,860 (2%) | 0% | 16.6 | 32,736 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 16.61 per share. | 16 Oct 2023 | 2,078 | 215,036 (0%) | 0% | 16.6 | 34,514 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Sale of securities on an exchange or to another person at price $ 16.61 per share. | 16 Oct 2023 | 1,198 | 92,378 (0%) | 0% | 16.6 | 19,898 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 16.61 per share. | 16 Oct 2023 | 665 | 118,146 (0%) | 0% | 16.6 | 11,045 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.61 per share. | 16 Oct 2023 | 861 | 85,658 (0%) | 0% | 16.6 | 14,300 | Common Stock |
| Janet M. Gunzburg | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 19.79 per share. | 18 Sep 2023 | 125 | 40,995 (0%) | 0% | 19.8 | 2,474 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 19.59 per share. | 18 Sep 2023 | 66 | 7,896 (0%) | 0% | 19.6 | 1,293 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 19.81 per share. | 18 Sep 2023 | 26 | 7,832 (0%) | 0% | 19.8 | 515 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 19.71 per share. | 18 Sep 2023 | 38 | 7,858 (0%) | 0% | 19.7 | 749 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 20.30 per share. | 12 Sep 2023 | 3,126 | 118,662 (0%) | 0% | 20.3 | 63,467 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 21.21 per share. | 12 Sep 2023 | 130 | 118,532 (0%) | 0% | 21.2 | 2,757 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2023 | 5,466 | 121,788 (0%) | 0% | - | Common Stock | |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 20.17 per share. | 12 Sep 2023 | 2,210 | 116,322 (0%) | 0% | 20.2 | 44,566 | Common Stock |
| Janet M. Gunzburg | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 20.30 per share. | 12 Sep 2023 | 897 | 41,157 (0%) | 0% | 20.3 | 18,212 | Common Stock |
| Janet M. Gunzburg | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 21.22 per share. | 12 Sep 2023 | 37 | 41,120 (0%) | 0% | 21.2 | 785 | Common Stock |
| Janet M. Gunzburg | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2023 | 2,404 | 42,054 (0%) | 0% | - | Common Stock | |
| Chaim Indig | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 21.21 per share. | 12 Sep 2023 | 262 | 1,245,291 (3%) | 0% | 21.2 | 5,556 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2023 | 11,260 | 1,251,846 (3%) | 0% | - | Common Stock | |
| Chaim Indig | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.30 per share. | 12 Sep 2023 | 6,293 | 1,245,553 (3%) | 0% | 20.3 | 127,767 | Common Stock |
| Evan Roberts | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2023 | 6,559 | 751,738 (2%) | 0% | - | Common Stock | |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 21.21 per share. | 12 Sep 2023 | 156 | 747,831 (2%) | 0% | 21.2 | 3,308 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 20.30 per share. | 12 Sep 2023 | 3,751 | 747,987 (2%) | 0% | 20.3 | 76,157 | Common Stock |
| David Linetsky | SVP, Life Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.03 per share. | 12 Sep 2023 | 5,689 | 213,484 (0%) | 0% | 8.0 | 45,683 | Common Stock |
| David Linetsky | SVP, Life Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2023 | 5,689 | 0 | - | - | Stock Option | |
| David Linetsky | SVP, Life Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2023 | 475 | 0 | - | - | Stock Option | |
| David Linetsky | SVP, Life Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2023 | 5,689 | 0 | - | - | Stock Option | |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 21.20 per share. | 12 Sep 2023 | 5 | 7,962 (0%) | 0% | 21.2 | 106 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 20.31 per share. | 12 Sep 2023 | 114 | 7,967 (0%) | 0% | 20.3 | 2,315 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 21.21 per share. | 12 Sep 2023 | 82 | 217,114 (0%) | 0% | 21.2 | 1,739 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 20.30 per share. | 12 Sep 2023 | 1,977 | 217,196 (0%) | 0% | 20.3 | 40,139 | Common Stock |
| David Linetsky | SVP, Life Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2023 | 273 | 8,081 (0%) | 0% | - | Common Stock | |
| David Linetsky | SVP, Life Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.71 per share. | 12 Sep 2023 | 5,689 | 219,173 (0%) | 0% | 4.7 | 26,795 | Common Stock |
| David Linetsky | SVP, Life Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.71 per share. | 12 Sep 2023 | 475 | 207,795 (0%) | 0% | 4.7 | 2,237 | Common Stock |
| David Linetsky | SVP, Life Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2023 | 3,279 | 207,320 (0%) | 0% | - | Common Stock | |
| Michael J. Davidoff | SVP, Payer Business | Sale of securities on an exchange or to another person at price $ 20.16 per share. | 12 Sep 2023 | 2,953 | 93,576 (0%) | 0% | 20.2 | 59,537 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2023 | 6,559 | 100,135 (0%) | 0% | - | Common Stock | |
| Michael J. Davidoff | SVP, Payer Business | Sale of securities on an exchange or to another person at price $ 20.30 per share. | 12 Sep 2023 | 3,462 | 96,673 (0%) | 0% | 20.3 | 70,289 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Sale of securities on an exchange or to another person at price $ 21.20 per share. | 12 Sep 2023 | 144 | 96,529 (0%) | 0% | 21.2 | 3,053 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 21.21 per share. | 12 Sep 2023 | 73 | 120,811 (0%) | 0% | 21.2 | 1,548 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2023 | 3,826 | 122,637 (0%) | 0% | - | Common Stock | |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 20.30 per share. | 12 Sep 2023 | 1,753 | 120,884 (0%) | 0% | 20.3 | 35,591 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 20.16 per share. | 12 Sep 2023 | 2,000 | 118,811 (0%) | 0% | 20.2 | 40,316 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2023 | 6,406 | 90,476 (0%) | 0% | - | Common Stock | |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.30 per share. | 12 Sep 2023 | 3,799 | 86,677 (0%) | 0% | 20.3 | 77,131 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.20 per share. | 12 Sep 2023 | 158 | 86,519 (0%) | 0% | 21.2 | 3,350 | Common Stock |
| Evan Roberts | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.03 per share. | 08 Sep 2023 | 30,000 | 745,179 (2%) | 0% | 2.0 | 60,900 | Common Stock |
| Evan Roberts | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2023 | 30,000 | 53,330 | - | - | Stock Options (Right to buy) | |
| Allison Hoffman | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.39 per share. | 24 Aug 2023 | 11,042 | 116,322 (0%) | 0% | 26.4 | 291,398 | Common Stock |
| Edward L. Cahill | Director | Grant, award, or other acquisition of securities at price $ 31.72 per share. | 31 Jul 2023 | 315 | 44,480 (0%) | 0% | 31.7 | 9,992 | Common Stock |
| Lainie Goldstein | Director | Grant, award, or other acquisition of securities at price $ 31.72 per share. | 31 Jul 2023 | 315 | 30,062 (0%) | 0% | 31.7 | 9,992 | Common Stock |
| Gillian Munson | Director | Grant, award, or other acquisition of securities at price $ 31.72 per share. | 31 Jul 2023 | 315 | 25,681 (0%) | 0% | 31.7 | 9,992 | Common Stock |
| Janet M. Gunzburg | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.72 per share. | 31 Jul 2023 | 272 | 39,650 (0%) | 0% | 31.7 | 8,628 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Sale of securities on an exchange or to another person at price $ 31.75 per share. | 21 Jul 2023 | 1,075 | 93,576 (0%) | 0% | 31.7 | 34,131 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.72 per share. | 14 Jul 2023 | 1,172 | 127,364 (0%) | 0% | 33.7 | 39,520 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.72 per share. | 14 Jul 2023 | 3,089 | 1,240,586 (3%) | 0% | 33.7 | 104,161 | Common Stock |
| Evan Roberts | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.72 per share. | 14 Jul 2023 | 1,781 | 715,179 (1%) | 0% | 33.7 | 60,055 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.72 per share. | 14 Jul 2023 | 1,948 | 204,041 (0%) | 0% | 33.7 | 65,687 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.72 per share. | 14 Jul 2023 | 1,122 | 94,651 (0%) | 0% | 33.7 | 37,834 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.72 per share. | 14 Jul 2023 | 624 | 118,811 (0%) | 0% | 33.7 | 21,041 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.72 per share. | 14 Jul 2023 | 807 | 84,070 (0%) | 0% | 33.7 | 27,212 | Common Stock |
| Lisa Egbuonu-Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2023 | 5,640 | 5,640 (0%) | 0% | 0 | Common Stock | |
| Lisa Egbuonu-Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2023 | 5,409 | 11,049 (0%) | 0% | 0 | Common Stock | |
| Balaji Gandhi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.87 per share. | 08 Jul 2023 | 861 | 84,877 (0%) | 0% | 28.9 | 24,857 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 26.21 per share. | 30 Jun 2023 | 201 | 128,536 (0%) | 0% | 26.2 | 5,268 | Common Stock |
| Janet M. Gunzburg | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 26.21 per share. | 30 Jun 2023 | 148 | 39,922 (0%) | 0% | 26.2 | 3,879 | Common Stock |
| Edward L. Cahill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 6,051 | 44,165 (0%) | 0% | 0 | Common Stock | |
| Lainie Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 6,051 | 29,747 (0%) | 0% | 0 | Common Stock | |
| Gillian Munson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 6,051 | 25,366 (0%) | 0% | 0 | Common Stock | |
| Michael Weintraub | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 6,051 | 180,537 (0%) | 0% | 0 | Common Stock | |
| Ramin Sayar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 6,051 | 18,245 (0%) | 0% | 0 | Common Stock | |
| Mark Douglas Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 6,051 | 22,163 (0%) | 0% | 0 | Common Stock | |
| Janet M. Gunzburg | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.79 per share. | 17 Jun 2023 | 117 | 39,774 (0%) | 0% | 31.8 | 3,719 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.78 per share. | 15 Jun 2023 | 27 | 7,808 (0%) | 0% | 31.8 | 858 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.79 per share. | 15 Jun 2023 | 67 | 7,835 (0%) | 0% | 31.8 | 2,130 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.45 per share. | 15 Jun 2023 | 40 | 7,902 (0%) | 0% | 33.5 | 1,338 | Common Stock |
| Gillian Munson | Director | Sale of securities on an exchange or to another person at price $ 30.06 per share. | 10 May 2023 | 3,555 | 19,315 (0%) | 0% | 30.1 | 106,864 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2023 | 12,453 | 0 | - | - | Stock Option | |
| Chaim Indig | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.03 per share. | 09 May 2023 | 12,453 | 1,243,675 (3%) | 0% | 8.0 | 99,998 | Common Stock |
| Janet M. Gunzburg | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.64 per share. | 01 May 2023 | 271 | 39,891 (0%) | 0% | 31.6 | 8,574 | Common Stock |
| Edward L. Cahill | Director | Grant, award, or other acquisition of securities at price $ 31.64 per share. | 28 Apr 2023 | 316 | 38,114 (0%) | 0% | 31.6 | 9,998 | Common Stock |
| Lainie Goldstein | Director | Grant, award, or other acquisition of securities at price $ 31.64 per share. | 28 Apr 2023 | 316 | 23,696 (0%) | 0% | 31.6 | 9,998 | Common Stock |
| Gillian Munson | Director | Grant, award, or other acquisition of securities at price $ 31.64 per share. | 28 Apr 2023 | 316 | 22,870 (0%) | 0% | 31.6 | 9,998 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Sale of securities on an exchange or to another person at price $ 33.13 per share. | 21 Apr 2023 | 1,075 | 95,773 (0%) | 0% | 33.1 | 35,615 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 32.09 per share. | 18 Apr 2023 | 7,452 | 716,960 (1%) | 0% | 32.1 | 239,167 | Common Stock |
| Janet M. Gunzburg | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 31.64 per share. | 16 Apr 2023 | 9,481 | 40,162 (0%) | 0% | 31.6 | 299,979 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 31.16 per share. | 14 Apr 2023 | 3,306 | 128,335 (0%) | 0% | 31.2 | 103,017 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.64 per share. | 14 Apr 2023 | 1,172 | 131,641 (0%) | 0% | 31.6 | 37,082 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.64 per share. | 14 Apr 2023 | 3,089 | 1,218,769 (3%) | 0% | 31.6 | 97,736 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 32.01 per share. | 14 Apr 2023 | 2,600 | 724,412 (2%) | 0% | 32.0 | 83,229 | Common Stock |
| Evan Roberts | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.64 per share. | 14 Apr 2023 | 1,781 | 727,012 (2%) | 0% | 31.6 | 56,351 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.64 per share. | 14 Apr 2023 | 1,948 | 205,989 (0%) | 0% | 31.6 | 61,635 | Common Stock |
| David Linetsky | SVP, Life Sciences | Grant, award, or other acquisition of securities at price $ 31.64 per share. | 14 Apr 2023 | 2,212 | 7,942 (0%) | 0% | 31.6 | 69,988 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.64 per share. | 14 Apr 2023 | 1,123 | 96,848 (0%) | 0% | 31.6 | 35,532 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 31.84 per share. | 14 Apr 2023 | 570 | 119,435 (0%) | 0% | 31.8 | 18,149 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2023 | 21,387 | 0 | - | - | Stock Option | |
| Amy Beth VanDuyn | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.84 per share. | 14 Apr 2023 | 21,387 | 120,005 (0%) | 0% | 0.8 | 17,965 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.64 per share. | 14 Apr 2023 | 623 | 98,618 (0%) | 0% | 31.6 | 19,712 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.64 per share. | 14 Apr 2023 | 807 | 87,851 (0%) | 0% | 31.6 | 25,533 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.83 per share. | 14 Apr 2023 | 2,113 | 85,738 (0%) | 0% | 31.8 | 67,248 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 32.01 per share. | 12 Apr 2023 | 200 | 728,793 (2%) | 0% | 32.0 | 6,402 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.15 per share. | 10 Apr 2023 | 3,775 | 132,813 (0%) | 0% | 30.1 | 113,816 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2023 | 7,081 | 136,588 (0%) | 0% | - | Common Stock | |
| Janet M. Gunzburg | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2023 | 3,115 | 42,270 (0%) | 0% | - | Common Stock | |
| Janet M. Gunzburg | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.15 per share. | 10 Apr 2023 | 1,123 | 41,147 (0%) | 0% | 30.1 | 33,858 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2023 | 14,587 | 1,229,743 (3%) | 0% | - | Common Stock | |
| Chaim Indig | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.15 per share. | 10 Apr 2023 | 7,885 | 1,221,858 (3%) | 0% | 30.2 | 237,733 | Common Stock |
| Evan Roberts | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.15 per share. | 10 Apr 2023 | 4,529 | 728,993 (2%) | 0% | 30.1 | 136,549 | Common Stock |
| Evan Roberts | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2023 | 8,497 | 733,522 (2%) | 0% | - | Common Stock | |
| David Linetsky | SVP, Life Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2023 | 210 | 5,793 (0%) | 0% | - | Common Stock | |
| David Linetsky | SVP, Life Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2023 | 4,248 | 209,737 (0%) | 0% | - | Common Stock | |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.15 per share. | 10 Apr 2023 | 1,800 | 207,937 (0%) | 0% | 30.2 | 54,270 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.14 per share. | 10 Apr 2023 | 63 | 5,730 (0%) | 0% | 30.1 | 1,899 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2023 | 7,081 | 105,052 (0%) | 0% | - | Common Stock | |
| Michael J. Davidoff | SVP, Payer Business | Sale of securities on an exchange or to another person at price $ 30.91 per share. | 10 Apr 2023 | 3,466 | 97,971 (0%) | 0% | 30.9 | 107,124 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.15 per share. | 10 Apr 2023 | 3,615 | 101,437 (0%) | 0% | 30.1 | 108,992 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.15 per share. | 10 Apr 2023 | 2,196 | 99,241 (0%) | 0% | 30.1 | 66,209 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2023 | 4,956 | 101,437 (0%) | 0% | - | Common Stock | |
| Balaji Gandhi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2023 | 4,956 | 91,501 (0%) | 0% | - | Common Stock | |
| Balaji Gandhi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.15 per share. | 10 Apr 2023 | 2,843 | 88,658 (0%) | 0% | 30.1 | 85,716 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 30.69 per share. | 03 Apr 2023 | 2,678 | 96,781 (0%) | 0% | 30.7 | 82,189 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 31.69 per share. | 03 Apr 2023 | 300 | 96,481 (0%) | 0% | 31.7 | 9,508 | Common Stock |
| Mark Douglas Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.71 per share. | 03 Apr 2023 | 7,000 | 23,112 (0%) | 0% | 4.7 | 32,970 | Common Stock |
| Mark Douglas Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2023 | 7,000 | 65,193 | - | - | Stock Option | |
| Mark Douglas Smith | Director | Sale of securities on an exchange or to another person at price $ 31.77 per share. | 03 Apr 2023 | 500 | 16,112 (0%) | 0% | 31.8 | 15,886 | Common Stock |
| Mark Douglas Smith | Director | Sale of securities on an exchange or to another person at price $ 30.69 per share. | 03 Apr 2023 | 6,500 | 16,612 (0%) | 0% | 30.7 | 199,482 | Common Stock |
| Balaji Gandhi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 21,428 | 86,545 (0%) | 0% | 0 | Common Stock | |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.81 per share. | 15 Mar 2023 | 148 | 5,409 (0%) | 0% | 34.8 | 5,152 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.67 per share. | 15 Mar 2023 | 18 | 5,347 (0%) | 0% | 33.7 | 606 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.82 per share. | 15 Mar 2023 | 44 | 5,365 (0%) | 0% | 34.8 | 1,532 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.85 per share. | 15 Mar 2023 | 26 | 5,557 (0%) | 0% | 33.8 | 880 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 39.55 per share. | 02 Feb 2023 | 11,378 | 205,489 (0%) | 0% | 39.5 | 449,989 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Sale of securities on an exchange or to another person at price $ 39.55 per share. | 02 Feb 2023 | 1,530 | 97,971 (0%) | 0% | 39.6 | 60,516 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Sale of securities on an exchange or to another person at price $ 39.12 per share. | 02 Feb 2023 | 5,983 | 99,501 (0%) | 0% | 39.1 | 234,048 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 02 Feb 2023 | 300 | 99,459 (0%) | 0% | 40 | 12,000 | Common Stock |
| Randy Rasmussen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 02 Feb 2023 | 4,765 | 145,594 (0%) | 0% | 40 | 190,600 | Common Stock |
| Edward L. Cahill | Director | Grant, award, or other acquisition of securities at price $ 37.49 per share. | 31 Jan 2023 | 266 | 37,798 (0%) | 0% | 37.5 | 9,972 | Common Stock |
| Lainie Goldstein | Director | Grant, award, or other acquisition of securities at price $ 37.49 per share. | 31 Jan 2023 | 266 | 23,380 (0%) | 0% | 37.5 | 9,972 | Common Stock |
| Gillian Munson | Director | Grant, award, or other acquisition of securities at price $ 37.49 per share. | 31 Jan 2023 | 266 | 22,554 (0%) | 0% | 37.5 | 9,972 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.71 per share. | 30 Jan 2023 | 712 | 137,304 (0%) | 0% | 4.7 | 3,354 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 712 | 0 | - | - | Stock Option | |
| Michael J. Davidoff | SVP, Payer Business | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 11,378 | 0 | - | - | Stock Option | |
| Michael J. Davidoff | SVP, Payer Business | Sale of securities on an exchange or to another person at price $ 38.00 per share. | 30 Jan 2023 | 3,265 | 105,484 (0%) | 0% | 38.0 | 124,082 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Sale of securities on an exchange or to another person at price $ 36.26 per share. | 30 Jan 2023 | 16,262 | 108,749 (0%) | 0% | 36.3 | 589,645 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Sale of securities on an exchange or to another person at price $ 35.89 per share. | 30 Jan 2023 | 12,293 | 125,011 (0%) | 0% | 35.9 | 441,144 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.03 per share. | 30 Jan 2023 | 11,378 | 136,592 (0%) | 0% | 8.0 | 91,365 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 36.07 per share. | 18 Jan 2023 | 649 | 129,507 (0%) | 0% | 36.1 | 23,407 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 1,288 | 101,216 (0%) | 0% | 35.4 | 45,608 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 2,124 | 99,092 (0%) | 0% | 35.4 | 75,211 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2023 | 31,064 | 130,156 (0%) | 0% | 0 | Common Stock | |
| Chaim Indig | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2023 | 70,601 | 1,270,502 (3%) | 0% | 0 | Common Stock | |
| Chaim Indig | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.00 per share. | 14 Jan 2023 | 55,346 | 1,215,156 (3%) | 0% | 35 | 1,937,110 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 3,288 | 1,237,094 (3%) | 0% | 35.4 | 116,428 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 6,010 | 1,231,084 (3%) | 0% | 35.4 | 212,814 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 31,183 | 1,199,901 (3%) | 0% | 35.4 | 1,104,190 | Common Stock |
| Evan Roberts | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 17,007 | 682,074 (1%) | 0% | 35.4 | 602,218 | Common Stock |
| Evan Roberts | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2023 | 45,184 | 727,258 (2%) | 0% | 0 | Common Stock | |
| Evan Roberts | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 2,805 | 699,081 (1%) | 0% | 35.4 | 99,325 | Common Stock |
| Evan Roberts | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 1,816 | 701,886 (1%) | 0% | 35.4 | 64,305 | Common Stock |
| Evan Roberts | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.00 per share. | 14 Jan 2023 | 2,233 | 725,025 (2%) | 0% | 35 | 78,155 | Common Stock |
| David Linetsky | SVP, Life Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2023 | 45,184 | 217,831 (0%) | 0% | 0 | Common Stock | |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.00 per share. | 14 Jan 2023 | 964 | 216,867 (0%) | 0% | 35 | 33,740 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 8,824 | 172,647 (0%) | 0% | 35.4 | 312,458 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 2,422 | 181,471 (0%) | 0% | 35.4 | 85,763 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 1,592 | 183,893 (0%) | 0% | 35.4 | 56,373 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 7,160 | 97,715 (0%) | 0% | 35.4 | 253,536 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 1,947 | 95,768 (0%) | 0% | 35.4 | 68,943 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2023 | 31,770 | 127,538 (0%) | 0% | 0 | Common Stock | |
| Michael J. Davidoff | SVP, Payer Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.00 per share. | 14 Jan 2023 | 2,324 | 125,214 (0%) | 0% | 35 | 81,340 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 1,239 | 104,875 (0%) | 0% | 35.4 | 43,873 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2023 | 19,768 | 100,767 (0%) | 0% | 0 | Common Stock | |
| Amy Beth VanDuyn | SVP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.00 per share. | 14 Jan 2023 | 1,008 | 99,759 (0%) | 0% | 35 | 35,280 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 698 | 86,351 (0%) | 0% | 35.4 | 24,716 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 1,126 | 85,225 (0%) | 0% | 35.4 | 39,872 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 4,226 | 80,999 (0%) | 0% | 35.4 | 149,643 | Common Stock |
| Randy Rasmussen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 1,496 | 107,043 (0%) | 0% | 35.4 | 52,973 | Common Stock |
| Randy Rasmussen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.41 per share. | 14 Jan 2023 | 1,868 | 105,175 (0%) | 0% | 35.4 | 66,146 | Common Stock |
| Randy Rasmussen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2023 | 45,184 | 150,359 (0%) | 0% | 0 | Common Stock | |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 33.17 per share. | 03 Jan 2023 | 597 | 703,702 (1%) | 0% | 33.2 | 19,801 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 32.37 per share. | 03 Jan 2023 | 899 | 704,299 (1%) | 0% | 32.4 | 29,099 | Common Stock |
| Evan Roberts | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 31.12 per share. | 03 Jan 2023 | 8,504 | 705,198 (1%) | 0% | 31.1 | 264,652 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 21.63 per share. | 31 Dec 2022 | 242 | 102,504 (0%) | 0% | 21.6 | 5,234 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2022 | 15,000 | 21,387 | - | - | Stock Option | |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 33.73 per share. | 20 Dec 2022 | 378 | 87,049 (0%) | 0% | 33.7 | 12,750 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.84 per share. | 20 Dec 2022 | 15,000 | 87,427 (0%) | 0% | 0.8 | 12,600 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.00 per share. | 16 Dec 2022 | 15 | 5,583 (0%) | 0% | 34 | 510 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.97 per share. | 16 Dec 2022 | 36 | 5,598 (0%) | 0% | 34.0 | 1,223 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 36.00 per share. | 13 Dec 2022 | 801 | 102,262 (0%) | 0% | 36 | 28,836 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 34.40 per share. | 13 Dec 2022 | 3,109 | 103,063 (0%) | 0% | 34.4 | 106,950 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 34.61 per share. | 13 Dec 2022 | 11,377 | 185,485 (0%) | 0% | 34.6 | 393,755 | Common Stock |
| David Linetsky | SVP, Life Sciences | Sale of securities on an exchange or to another person at price $ 29.78 per share. | 09 Dec 2022 | 26,837 | 196,862 (0%) | 0% | 29.8 | 799,072 | Common Stock |
| Randy Rasmussen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.17 per share. | 09 Dec 2022 | 8,183 | 117,685 (0%) | 0% | 30.2 | 246,870 | Common Stock |
| Randy Rasmussen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.77 per share. | 09 Dec 2022 | 7,395 | 108,539 (0%) | 0% | 31.8 | 234,913 | Common Stock |
| Randy Rasmussen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.40 per share. | 09 Dec 2022 | 1,751 | 115,934 (0%) | 0% | 31.4 | 54,982 | Common Stock |
| Randy Rasmussen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.34 per share. | 06 Nov 2022 | 5,636 | 125,868 (0%) | 0% | 24.3 | 137,180 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 27.14 per share. | 02 Nov 2022 | 9,955 | 72,827 (0%) | 0% | 27.1 | 270,214 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 27.96 per share. | 02 Nov 2022 | 400 | 72,427 (0%) | 0% | 28.0 | 11,185 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Sale of securities on an exchange or to another person at price $ 26.44 per share. | 02 Nov 2022 | 8,986 | 82,782 (0%) | 0% | 26.4 | 237,559 | Common Stock |
| Edward L. Cahill | Director | Grant, award, or other acquisition of securities at price $ 27.32 per share. | 31 Oct 2022 | 366 | 37,532 (0%) | 0% | 27.3 | 9,999 | Common Stock |
| Lainie Goldstein | Director | Grant, award, or other acquisition of securities at price $ 27.32 per share. | 31 Oct 2022 | 366 | 23,114 (0%) | 0% | 27.3 | 9,999 | Common Stock |
| Gillian Munson | Director | Grant, award, or other acquisition of securities at price $ 27.32 per share. | 31 Oct 2022 | 366 | 22,288 (0%) | 0% | 27.3 | 9,999 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Sale of securities on an exchange or to another person at price $ 25.26 per share. | 18 Oct 2022 | 1,075 | 106,114 (0%) | 0% | 25.3 | 27,155 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.48 per share. | 14 Oct 2022 | 1,128 | 106,172 (0%) | 0% | 22.5 | 25,357 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.48 per share. | 14 Oct 2022 | 3,660 | 1,240,382 (3%) | 0% | 22.5 | 82,277 | Common Stock |
| Evan Roberts | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.48 per share. | 14 Oct 2022 | 2,140 | 713,702 (1%) | 0% | 22.5 | 48,107 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.48 per share. | 14 Oct 2022 | 1,749 | 223,699 (0%) | 0% | 22.5 | 39,318 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.48 per share. | 14 Oct 2022 | 1,123 | 107,189 (0%) | 0% | 22.5 | 25,245 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.48 per share. | 14 Oct 2022 | 623 | 91,768 (0%) | 0% | 22.5 | 14,005 | Common Stock |
| Randy Rasmussen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.48 per share. | 14 Oct 2022 | 1,219 | 131,504 (0%) | 0% | 22.5 | 27,403 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.71 per share. | 16 Sep 2022 | 14 | 5,634 (0%) | 0% | 27.7 | 388 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.71 per share. | 16 Sep 2022 | 35 | 5,648 (0%) | 0% | 27.7 | 970 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Sale of securities on an exchange or to another person at price $ 27.60 per share. | 16 Sep 2022 | 1,296 | 108,312 (0%) | 0% | 27.6 | 35,773 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 28.58 per share. | 15 Sep 2022 | 1,290 | 107,300 (0%) | 0% | 28.6 | 36,866 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.19 per share. | 12 Sep 2022 | 1,359 | 108,590 (0%) | 0% | 29.2 | 39,669 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2022 | 2,649 | 109,949 (0%) | 0% | - | Common Stock | |
| Chaim Indig | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.19 per share. | 12 Sep 2022 | 3,496 | 1,244,042 (3%) | 0% | 29.2 | 102,048 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2022 | 5,457 | 1,247,538 (3%) | 0% | - | Common Stock | |
| Evan Roberts | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2022 | 3,178 | 717,878 (2%) | 0% | - | Common Stock | |
| Evan Roberts | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.19 per share. | 12 Sep 2022 | 2,036 | 715,842 (1%) | 0% | 29.2 | 59,431 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.19 per share. | 12 Sep 2022 | 626 | 225,448 (0%) | 0% | 29.2 | 18,273 | Common Stock |
| David Linetsky | SVP, Life Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2022 | 1,589 | 226,074 (0%) | 0% | - | Common Stock | |
| Michael J. Davidoff | SVP, Payer Business | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2022 | 2,649 | 110,961 (0%) | 0% | - | Common Stock | |
| Michael J. Davidoff | SVP, Payer Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.19 per share. | 12 Sep 2022 | 1,353 | 109,608 (0%) | 0% | 29.2 | 39,494 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.19 per share. | 12 Sep 2022 | 822 | 92,391 (0%) | 0% | 29.2 | 23,994 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2022 | 1,854 | 93,213 (0%) | 0% | - | Common Stock | |
| Randy Rasmussen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.19 per share. | 12 Sep 2022 | 1,160 | 132,723 (0%) | 0% | 29.2 | 33,860 | Common Stock |
| Randy Rasmussen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2022 | 3,178 | 133,883 (0%) | 0% | - | Common Stock | |
| Allison Hoffman | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.85 per share. | 24 Aug 2022 | 6,916 | 107,300 (0%) | 0% | 23.9 | 164,947 | Common Stock |
| Edward L. Cahill | Director | Grant, award, or other acquisition of securities at price $ 23.49 per share. | 29 Jul 2022 | 372 | 37,166 (0%) | 0% | 23.5 | 8,738 | Common Stock |
| Lainie Goldstein | Director | Grant, award, or other acquisition of securities at price $ 23.49 per share. | 29 Jul 2022 | 372 | 22,748 (0%) | 0% | 23.5 | 8,738 | Common Stock |
| Gillian Munson | Director | Grant, award, or other acquisition of securities at price $ 23.49 per share. | 29 Jul 2022 | 372 | 21,922 (0%) | 0% | 23.5 | 8,738 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 21 Jul 2022 | 1,404 | 108,312 (0%) | 0% | 25 | 35,100 | Common Stock |
| Allison Hoffman | General Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.35 per share. | 14 Jul 2022 | 1,128 | 114,216 (0%) | 0% | 22.4 | 25,211 | Common Stock |
| Chaim Indig | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.35 per share. | 14 Jul 2022 | 3,660 | 1,242,081 (3%) | 0% | 22.4 | 81,801 | Common Stock |
| Evan Roberts | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.35 per share. | 14 Jul 2022 | 2,140 | 714,700 (1%) | 0% | 22.4 | 47,829 | Common Stock |
| David Linetsky | SVP, Life Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.35 per share. | 14 Jul 2022 | 1,315 | 224,485 (0%) | 0% | 22.3 | 29,390 | Common Stock |
| Michael J. Davidoff | SVP, Payer Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.35 per share. | 14 Jul 2022 | 793 | 109,716 (0%) | 0% | 22.4 | 17,724 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.35 per share. | 14 Jul 2022 | 624 | 91,359 (0%) | 0% | 22.3 | 13,946 | Common Stock |
| Randy Rasmussen | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.35 per share. | 14 Jul 2022 | 1,219 | 130,705 (0%) | 0% | 22.4 | 27,245 | Common Stock |
| Gillian Munson | Director | Sale of securities on an exchange or to another person at price $ 25.92 per share. | 11 Jul 2022 | 1,384 | 21,550 (0%) | 0% | 25.9 | 35,872 | Common Stock |
| Gillian Munson | Director | Sale of securities on an exchange or to another person at price $ 25.21 per share. | 11 Jul 2022 | 1,221 | 22,934 (0%) | 0% | 25.2 | 30,784 | Common Stock |
| Amy Beth VanDuyn | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2022 | 20,000 | 36,387 | - | - | Stock Option (Right to Buy) | |
| Amy Beth VanDuyn | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.84 per share. | 07 Jul 2022 | 20,000 | 91,983 (0%) | 0% | 0.8 | 16,800 | Common Stock |
| Edward L. Cahill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 7,397 | 36,794 (0%) | 0% | 0 | Common Stock | |
| Lainie Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 7,397 | 22,376 (0%) | 0% | 0 | Common Stock | |
| Allison Hoffman | General Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 21.26 per share. | 30 Jun 2022 | 245 | 115,344 (0%) | 0% | 21.3 | 5,209 | Common Stock |
| Gillian Munson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 7,397 | 24,155 (0%) | 0% | 0 | Common Stock | |
| Michael Weintraub | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 7,397 | 174,486 (0%) | 0% | 0 | Common Stock | |
| Ramin Sayar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 7,397 | 12,194 (0%) | 0% | 0 | Common Stock | |
| Randy Rasmussen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 21.26 per share. | 30 Jun 2022 | 581 | 131,924 (0%) | 0% | 21.3 | 12,352 | Common Stock |